Angiotensin Converting Enzyme Inhibitors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Angiotensin Converting Enzyme Inhibitors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

  • Transparency Market Research
  • Ongoing
  • Healthcare

Report Description

1
1

Angiotensin converting enzyme inhibitors are a group of drugs used for the treatment of heart failure, high blood pressure (hypertension), or decrease complications of myocardial infarction (heart attack). These drugs are also useful in slowing down kidney disease progression in patients with chronic kidney disease or kidney disease in diabetic patients. The mechanism of action of angiotensin converting enzyme inhibitors is to decrease the amount of angiotensin II produced. Angiotensin II has an effect on the body to increase pressure in the kidney, blood volume, and blood pressure.

Angiotensin converting enzyme inhibitors widen the blood vessels by lowering the amount of angiotensin II in the body. These also increase the amount of urine produced by kidneys. This results in lowering of pressure in the kidney, lowering blood volume, and blood pressure. There is a drop in aldosterone and noradrenalin levels due to inhibition of angiotensin II by angiotensin converting enzyme inhibitors which helps in reducing blood pressure. Angiotensin converting enzyme inhibitors also increases bradykinin which widens the blood vessels, thereby decreasing blood pressure. These also cause a few side effects depending upon which type of angiotensin converting enzyme inhibitors are taken. Side effects include swelling of face or airways (angioedema), reduced kidney function, dizziness, high potassium levels (hyperkalemia), dry cough, and low blood pressure (hypotension).

Increase in prevalence of high blood pressure is the major factor driving the angiotensin converting enzyme inhibitors market. According to the World Health Organization, over 1 in 5 adults suffer from high blood pressure globally. Complications of high blood pressure cause approximately 9.4 million deaths across the world each year. Rise in prevalence of heart failure also propels the angiotensin converting enzyme inhibitors market. According to the Centers for Disease Control and Prevention (CDC), approximately 5.7 million adults in the U.S. suffer from heart failure each year, nearly half of these people die within five years of diagnosis.

The global angiotensin converting enzyme inhibitors market can be segmented based on disease type, dosage form, and distribution channel. In terms of disease type, the Angiotensin Converting Enzyme Inhibitors market can be divided into heart failure, high blood pressure (hypertension), heart attack, and kidney disease. Based on dosage form, the global angiotensin converting enzyme inhibitors market can be categorized into oral tablets and oral solution. Based on distribution channel, the angiotensin converting enzyme inhibitors market can be classified into online pharmacies, retail pharmacies, and hospital pharmacies.

Geographically, the global angiotensin converting enzyme inhibitors market can be segmented into Latin America, Asia Pacific, Europe, North America, and Middle East & Africa. North America held the largest angiotensin converting enzyme inhibitors market share in 2016. Rise in prevalence of heart failure, heart attack, and high blood pressure drive the angiotensin converting enzyme inhibitors market in the region. Europe held the second largest market share in 2016. Increase in prevalence of kidney disease and high blood pressure in the region fuel the growth of the market in the region. The angiotensin converting enzyme inhibitors market in Asia Pacific is anticipated to be driven by increase in government initiatives for the health care sector especially in countries such as India and China. The global angiotensin converting enzyme inhibitors market in Middle East & Africa is anticipated to be driven by initiatives taken by the governments in the health care sector. The angiotensin converting enzyme inhibitors market in Latin America is anticipated to experience strong growth during the forecast period owing to the government initiatives for heart diseases in the region.

Key players in the global angiotensin converting enzyme inhibitors market include Bristol-Myers Squibb Company, Par Pharmaceutical Companies, Inc., UCB, Inc., Pfizer, Inc., and AstraZeneca.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Have query on this report?

Make an Enquiry

Success Stories

Our Clients

Tell Us What You Need and We’ll Get Back with the Best Solutions Available.

*
*
*

get in touch

Location :

State Tower, 90 State Street, Suite 700, Albany NY - 12207, United States

Call Us :

US/Canada toll free : 866-997-4948

Tel : +1-518-621-2074